Making ‘triple elimination’ accessible through antenatal testing

This article is in partnership with:

Dr. Aatish Madhiwala

MD MBA, President – Premier Medical Corporation

Medical diagnostics company aims to make antenatal screening for HIV, syphilis and hepatitis B more accessible to low- and middle-income countries through its US$1 Triple Elimination Testing Bundle.


Human immunodeficiency virus (HIV), syphilis and hepatitis B remain a major public health concern, particularly in resource-limited settings.

Importance of antenatal testing

The World Health Organization (WHO) encourages a coordinated approach to eliminating mother-to-child transmission, for which antenatal testing is becoming a key component.1 “Countries need to identify prevalent diseases, diagnose them, and ensure people receive treatment,” explains Dr Aatish Madhiwala, President of Premier Medical Corporation (PMC). “Antenatal testing facilitates diagnosis, enabling timely treatment and helps to prevent mother-to-child transmission in support of global triple elimination efforts.”

Mass manufacture rapid diagnostic tests

For 30 years, PMC has been developing, manufacturing and distributing high-quality rapid diagnostic tests for a wide array of diseases to over 100 countries worldwide. Its portfolio includes several WHO-prequalified tests, including an HIV/syphilis combination test, alongside a CE-marked hepatitis B test. The company is also developing a single test covering all three infections.

We can mass manufacture rapid diagnostic tests while maintaining the highest quality

“We can mass manufacture rapid diagnostic tests while maintaining the highest quality,” says Dr Madhiwala. “We wouldn’t send out a test we wouldn’t use on ourselves and our own families.” Alongside its diagnostic products, digital training tools are included, with online learning resources designed to help healthcare workers understand the diseases and interpret results correctly.

Funding and procurement

With global health budgets under increasing pressure, affordability remains a significant barrier to expanding antenatal screening. In September 2026, PMC announced its Triple Elimination Testing Bundle in association with Impact Nexus Africa, a US$1 ex-works offer designed to help low- and middle-income countries.

“This triple bundle is 22% to 46% lower in commodity price than procuring equivalent dual HIV/syphilis and HBsAg tests separately 2,” explains Dr Madhiwala. “The ability to get three different tests at a highly discounted price is a huge advantage for many countries. This is the most efficient way to use healthcare budgets to achieve maximum impact.”

More from AMR & Infectious Diseases